{"name":"Eagle Pharmaceuticals","slug":"eagle","ticker":"EGRX","exchange":"NASDAQ","domain":"eagleus.com","description":"Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development","hq":"Woodcliff Lake, NJ","founded":0,"employees":"134","ceo":"Scott Tarriff","sector":"Oncology / Injectable Specialty Pharma","stockPrice":0.25,"stockChange":0,"stockChangePercent":0,"marketCap":"$3M","metrics":{"revenue":316610000,"revenueGrowth":-12.8,"grossMargin":69.8,"rdSpend":34088000,"netIncome":35642000,"cash":15354000,"dividendYield":0,"peRatio":2.5,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Bendeka patent cliff ($10.0M at risk)","drug":"Bendeka","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Belrapzo patent cliff ($5.0M at risk)","drug":"Belrapzo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","slug":"ryanodex-and-standard-of-care","indication":"Malignant hyperthermia crisis (acute treatment)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAL02","genericName":"CAL02","slug":"cal02","indication":"Treatment of rheumatoid arthritis","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","slug":"dantrolene-sodium-for-injectable-suspension","indication":"Malignant hyperthermia","status":"phase_2"}]}],"pipeline":[{"name":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","slug":"ryanodex-and-standard-of-care","phase":"phase_3","mechanism":"Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.","indications":["Malignant hyperthermia crisis (acute treatment)","Malignant hyperthermia susceptibility (prophylaxis)"],"catalyst":""},{"name":"CAL02","genericName":"CAL02","slug":"cal02","phase":"phase_2","mechanism":"CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.","indications":["Treatment of rheumatoid arthritis"],"catalyst":""},{"name":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","slug":"dantrolene-sodium-for-injectable-suspension","phase":"phase_2","mechanism":"Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.","indications":["Malignant hyperthermia","Spinal cord injury","Stroke","Spinal cord injury associated with autonomic dysreflexia","Cerebral palsy"],"catalyst":""}],"recentEvents":[{"date":"2023-08-09","type":"earnings","headline":"Eagle Pharmaceuticals Reports Second Quarter 2023 Financial Results","summary":"Eagle Pharmaceuticals reported revenue of $24.4 million for the second quarter of 2023, a decrease of 14.1% compared to the same period in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-06-01","type":"deal","headline":"Eagle Pharmaceuticals Announces Exclusive Distribution Agreement with Sandoz for Bendeka","summary":"Eagle Pharmaceuticals has entered into an exclusive distribution agreement with Sandoz for Bendeka, a bendamustine hydrochloride injection.","drugName":"","sentiment":"positive"},{"date":"2022-12-15","type":"regulatory","headline":"FDA Approves Belrapzo for the Treatment of Acute Lymphoblastic Leukemia","summary":"The FDA has approved Belrapzo, a belinostat injection, for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPellmQlE5aURaaXY0ZmkxV3RKalRBZDhvQXM0NnVUV1Y1clpBMWdTZjY3ZjZoWkQtZ1BYbjNROWVBUS1SN3lHWTd0QzNyTm4xeGZ1Z1MwWnZ4NWQzNmlUZVU4Y2ExY2h6ZllQQVhNWG5ucXhVaXRZMkFPZmI3bTM5ZkJLR2s1MjFwb3JYVW9WQnZhR2VDdjVWTndOcXIxeTc4UDcyVDJ6YVNoWmZ5SGl3ZUxCVVpMRE00QlZ6OW1HMkxLaTg?oc=5","date":"2026-01-19","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Eagle Pharmaceuticals: Is EGRX the Comeback Story No One Saw Coming? - AD HOC NEWS","headline":"The Truth About Eagle Pharmaceuticals: Is EGRX the Comeback Story No One Saw Coming?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM09tOFZoZXU0WXpWUU9fMlc4a1hTMkRRWHNZT3hYcF9oY3BoLVJ2a25rNm9IM0g5dm1pRzkzbHNQNDJrX1NsQ1FfZTd1ZnhXbDZTN1FPNTlvd1pVUkhWM2owRmgzWWhTOC1XMktQc19rYzZIdTY0UzZTN2JpeE02ME1DSTNqZW1rNkpzd2JEWjBEVXR4UUtBQ21kNUxpRGdRV1lJ?oc=5","date":"2026-01-14","type":"regulatory","source":"Stock Titan","summary":"Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan","headline":"Only FDA-approved post-surgery nausea drug shifts to new owner","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUTAxalBtR1ZuUUhDeEQyY3FnZDBQLXlpZXgzNzd3QjhHRmdOdVc4X1JGcUtKRVl5VXdoX2J6aVpwaTBKSGRUTWNHOTFPWlpkQ0JFYWViRXpOdUtJSzQ2YUJFYXBwcW1xMGdOT3pMeGhFNUxtS29iT3lCVThwWmRmbi14eTJtQTU5TzFFZnc4bFJaMi1rclIyc2tzWnJCb2djbWJfMlhIa0IyV1RaTnlQT2gxUlpOeFJDY2d3?oc=5","date":"2025-10-15","type":"earnings","source":"Stock Titan","summary":"Unaudited Q2 2025 financials available — Eagle Pharmaceuticals posts three- and six-month statements - Stock Titan","headline":"Unaudited Q2 2025 financials available — Eagle Pharmaceuticals posts three- and six-month statements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPTlhVdi1pNGJfSG1lQ3EwSVdwS1l2M05ET1hlSDV0X0FmbkNOZ0U0dEhoV1pFWXh5Z0htT19qaG15QmhUVEFSZVp0SVhWUUo4Y052ZVVHQ2V6dG41NWRNajBCYmhGMkVIUEdpM1doaW1ISzVCQUJNY0JKMEVBaXhjbzEzUkE3dWN6YnVqY1ZWNjByWV9Ta0c0SXpKV1ZOUTNUaVhIRG9CSjVfWmVvRTYzT1JnLXdzYVJJOGc?oc=5","date":"2025-10-06","type":"earnings","source":"Stock Titan","summary":"Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan","headline":"Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5rUWFuZXRreHh0eVMwRmV2ZEZYd0JjcjRubTlwUHFITUp4LWFYSjZjQldfRWJ1aVRuakhGYWtmSE50QklnN3czTkdRY2pwNDN5dFZB?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"EGRX Stock Price, News & Analysis - Stock Titan","headline":"EGRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQ2tNT3pWeUViLUVOdXc0VFg4dFFRbnBmUkhNRGR4M1RqcGw4UXNIUWdjUmJ3Q0M3NzEyVGdvcVJlRHJ6QnYwS3FBOTVXVncyQktqQ3FtdElqLVZLMHVEZi1hMzVfckRZQ2ZRb3ZoT2lGRWVZREJ6UFBRbjluTkpLMTB5REdIMldOWkdJZjdiMHhNamlIMmRHNDAxX0JRaGY1Sk5haGxwUmpTcktIVWhSaUF6WlZCZWs0WU1F?oc=5","date":"2025-03-31","type":"pipeline","source":"Stock Titan","summary":"Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan","headline":"Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale","sentiment":"neutral"},{"date":"2024-12-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-11-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxORURFNC1PZXAxZWJsR2hjMnVKQ25jdjlyZVc3dkh6cGFkbG1FcWlHbjhMZEpFcnU4OURjRWlnRzZyd05lNnFEYm1DSnl4Zk0xUFh4eE1pWUVMTENWd3U4MkVNeUpBcEFNMTJkRGQ3em9QMy1kUHpEWkkxNW15NjdSbjRhR3ZEeUJud3ZsOFFRQnlkRWRMS3B0XzFITW5SSXF3TzN5MFNQR1NES29kVVFV?oc=5","date":"2024-11-15","type":"pipeline","source":"Stock Titan","summary":"Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension - Stock Titan","headline":"Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension","sentiment":"neutral"},{"date":"2024-11-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOcXE1WkpoN3ZHUFdDU3J0ZFlmUF8yLXhYVnhYZy04UW1oMThLc2JKd3prZDhKaS02YU50aUNzdXJ1Z2swdVhrMWdwX25pdXlnX2RIRElVc3A5R2sxVV9uOGZ1ZkJnTWNGdzVMMExtSGV2Uzk0aXJOZ09kQ2VnZkFJamJEZVd1bFFVUklMaXBB?oc=5","date":"2022-03-30","type":"pipeline","source":"William Blair","summary":"Eagle Pharmaceuticals and Acacia Pharma Transaction - William Blair","headline":"Eagle Pharmaceuticals and Acacia Pharma Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE1SaU9ybjRrRmlNOVdiMTRZRW9ZaXlBNUNfVXZTTWo2YzRVVVRDNEpDR3hUNklnY2FNUm40Rm9TSHhlZmpIWFk4YQ?oc=5","date":"2020-12-09","type":"deal","source":"StockInvest.us","summary":"Eagle Pharmaceuticals Stock Price Forecast. Should You Buy EGRX? - StockInvest.us","headline":"Eagle Pharmaceuticals Stock Price Forecast. Should You Buy EGRX?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1pd09CN0g1eDJOejM0NEg1QWZKMUVXTXQ3bzYyU3dEbDRsaHpmSFlLRTBma3lpRVNiLVl6OTNvQTNHYkVDUTFpXzg5ZXo3R2p2STRZVC1yT21SbVoxV0duaGxuYzVmRlFwRldDUGptdVRadjM3bnZ2U1Nn?oc=5","date":"2020-05-25","type":"pipeline","source":"Proactive Investors","summary":"Eagle Pharmaceuticals Share Price - EGRX, RNS News, Articles, Quotes, & Charts (NASDAQ:EGRX) - Proactive Investors","headline":"Eagle Pharmaceuticals Share Price - EGRX, RNS News, Articles, Quotes, & Charts (NASDAQ:EGRX)","sentiment":"neutral"}],"patents":[{"drugName":"Bendeka","drugSlug":"bendamustine-hydrochloride","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10000000},{"drugName":"Belrapzo","drugSlug":"belinostat","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":5000000}],"drugCount":3,"phaseCounts":{"phase_3":1,"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Bristol-Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology","Injectable Specialty Pharma"],"financials":{"source":"sec_edgar+yahoo","revenue":316610000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":316610000,"period":"2022-12-31"},{"value":171546000,"period":"2021-12-31"},{"value":171546000,"period":"2021-12-31"},{"value":187802000,"period":"2020-12-31"},{"value":187802000,"period":"2020-12-31"}],"grossProfit":221674000,"grossProfitHistory":[{"period":"2022-12-31","value":221674000},{"period":"2021-12-31","value":129366000}],"rdSpend":34088000,"rdSpendHistory":[{"period":"2022-12-31","value":34088000},{"period":"2021-12-31","value":51275000}],"sgaSpend":106626000,"operatingIncome":80960000,"operatingIncomeHistory":[{"period":"2022-12-31","value":80960000},{"period":"2021-12-31","value":2769000}],"netIncome":35642000,"netIncomeHistory":[{"period":"2022-12-31","value":35642000},{"period":"2021-12-31","value":-8627000}],"eps":2.73,"epsHistory":[{"period":"2022-12-31","value":2.73},{"period":"2021-12-31","value":-0.66}],"cash":55321000,"cashHistory":[{"period":"2022-12-31","value":55321000},{"period":"2021-12-31","value":97659000}],"totalAssets":406160000,"totalLiabilities":172600000,"totalDebt":64000000,"equity":233560000,"operatingCashflow":50701000,"operatingCashflowHistory":[{"period":"2022-12-31","value":50701000},{"period":"2021-12-31","value":28219000}],"capex":-178000,"capexHistory":[{"period":"2022-12-31","value":-178000},{"period":"2021-12-31","value":-323000}],"freeCashflow":50523000,"dividendsPaid":null,"buybacks":-18004000,"employees":134,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.25,"previousClose":0.25,"fiftyTwoWeekHigh":3.87,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"0.001 - 3.87","fiftyDayAverage":0.3,"twoHundredDayAverage":1.2,"beta":0.6,"enterpriseValue":61970116,"forwardPE":0.1,"priceToBook":0.01,"priceToSales":0.01,"enterpriseToRevenue":0.24,"enterpriseToEbitda":0.99,"pegRatio":0,"ebitda":62327000,"ebitdaMargin":24.2,"freeCashflow":38314752,"operatingCashflow":-9318000,"totalDebt":72454000,"debtToEquity":28.7,"currentRatio":2.16,"returnOnAssets":6.6,"returnOnEquity":4.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":55.2,"sharesOutstanding":13157553,"floatShares":5908682,"sharesShort":350531,"shortRatio":3.91,"shortPercentOfFloat":2.7,"epsTrailing":0.1,"epsForward":3.48,"revenuePerShare":19.68,"bookValue":19.25,"officers":[{"age":62,"name":"Mr. Michael  Graves","title":"CEO & Chairman"},{"age":51,"name":"Mr. Christopher  Krawtschuk CPA","title":"CFO and Principal Financial & Accounting Officer"},{"age":45,"name":"Mr. Daniel  O'Connor","title":"Executive VP, Chief Strategy Officer & Head of Corporate Development"},{"age":null,"name":"Dr. Valentin R. Curt M.D.","title":"Senior Vice President of Clinical Drug Development"},{"age":57,"name":"Ms. Debra Marie Hussain","title":"Senior VP & Head of Commercial"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.eagleus.com","phone":"201 326 5300"}}